Then they should come up with a new technical term instead of recycling a very well defined term used exclusively for an x-ray system.
You could still use the Tomography part -
Short answer: In medicine, “computed tomography (CT)” is defined as an imaging modality that uses X‑rays plus computer processing to reconstruct tomographic (slice) images, and then often 3D volumes, from multiple projections. That term is not normally applied to arbitrary technologies that simply “combine a group of scans into one image” unless they are tomographic reconstructions, and outside of X‑ray it is conventional to qualify it (e.g., “optical coherence tomography,” “photoacoustic tomography”) rather than just calling it CT
What it’s building: Mobile MRI clinics for early cancer detection
Why it’s a fav: We know early detection saves lives, but the healthcare system doesn’t have enough MRI machines to screen everyone regularly. They are just too expensive — costing millions to buy and tens of thousands a year to maintain. Adialante is trying to solve this problem. The startup says it has designed a compact MRI unit that can be transported in a small truck. Adialante’s business model is to bring these machines to clinics and charge $250 a scan. The company’s massive but worthwhile ambition is to change MRI scans from being reserved for symptomatic patients into a routine annual screening.
So, I asked Gemini: (note: the response is much longer, this is just a short summary).
What is the scientific and clinical evidence that a selective GalR1 antagonist would be helpful in Alzheimers?
Response:
The therapeutic rationale for deploying a selective Galanin Receptor 1 (GalR1) antagonist in Alzheimer’s disease (AD) centers on a long-standing mechanistic paradox in geroscience: the dramatic hypertrophy and hyper-innervation of galaninergic fibers surrounding surviving cholinergic basal forebrain (CBF) neurons in late-stage AD (Counts et al., 2008).
While early hypotheses debated whether this galanin overexpression is purely neuroprotective or neurodestructive, preclinical and mechanistic evidence strongly indicates that signaling through the GalR1 subtype actively drives cognitive deficits by crushing cholinergic transmission .
I own this device and reached an identical conclusion. Another reason why the subscription value is lacking is the lack of multi user support (for families). The machine (and app) assume all the readings are for the same person.
Breaking news for people who want to look hot, be young and not die. A few years ago, two college dropouts told me they could accelerate longevity by building a faster AI chip. I invested, and they just pulled it off.
What it means:
10x more throughput (tokens per second) for the same power footprint
Dramatically lower operational costs for executing today’s frontier models
Run far larger, more capable AI models within the same power and thermal budget, because a transformer-specific chip spends a fraction of the energy per token that a general-purpose GPU does
Rob and Gavin’s approach resonated with me because solving aging is a gigantic combinatorial search problem. The chemical space of small, drug-like molecules has around 10^60 possibilities.
These compounds need to be mapped against a human proteome derived from 20,000 genes, including 1,600 transcription factors, and a dense web of interactions among them. The size of the combinatorial space is problematic. You need to identify which targets to modulate, within specific cellular lineages, at exact dosages, and in optimal temporal sequences. Traditional high precision physics simulations are too slow to brute force the problem. You can shortcut it with AI inference, using frontier neural networks as hyper fast surrogate models to predict biological interactions instantly. By hardwiring transformer logic into silicon, Etched offers the infrastructure needed to run these massive biological foundation models at scale. I’m surprised and impressed they were able to pull this off, and so quickly.
For a healthy biohacker taking an SGLT2 inhibitor like canagliflozin off-label (for longevity/metabolic reasons), a specific hazard is euglycemic DKA: the drug spills glucose into urine, so blood sugar stays normal while ketones can quietly climb—meaning the usual warning sign (high glucose) never appears, and this risk spikes during their common practices like fasting, low-carb/keto eating, hard training, illness, or alcohol.
Pairing the SGLT2i with continuous ketone monitoring can de-risks it by watching β-hydroxybutyrate directly and continuously: instead of relying on a reassuring-but-misleading glucose reading, you’d see an upward, unbraked ketone trend early… perhaps well before nausea or malaise and could act (eat carbs, hydrate, hold the drug, seek care) while it’s still a minor course-correction rather than an emergency.
(Worth stressing, though: the low-range accuracy of consumer ketone sensors is still unproven, and a sensor only buys warning time—it doesn’t make the combination inherently safe, so a knowledgeable clinician in the loop matters.)
@adssx nor sure if you want to cross link to your flozin thread
A recent story on the Katalyst. The guy pans it, but I think it seems pretty interesting.
I Bought the $3,000 Fitness Suit That Electrocutes You.
Celebrities like George Clooney have praised the expensive Katalyst suit. For me, it derailed my other exercises and made me reassess my obsession with fitness and efficiency.
FWIW 20 mg of telimisartan is the smallest dose. Goes up to 40 and 80. A wide range to experiment with.
Not knowing of a possible benefit of taking PM, or even another 20mg in PM, I’m taking upon waking and my numbers drop 5pts off both high and low numbers. Just 5 pts at 20mg. 129/86 to 124/82 with fluctuations. One might ask is a drug worth such a small gain? AND is lowering where I’m at does it have any anti aging benefit? Its my resting heart rate, RHR that I’m frustrated with at 72yo good shape. It running high 70’s. 20mg telimisartan did drop that 5-10 beets.
I took 200mg modifinil this am and RHR is 84 with 20mg telimisartan. I’m not surprised that handfulls of pills that some or some combo is raising my RHR. I don’t have a ring to measure HRV.
I buy my telimisartan etc from alldaychemist.com. So I can play with dosing all I want, just buy more.
Another reason why I’m experimenting with telimisartan is that it also helps glucose control and when I read up it also had a bigger health foot print like the recent posts here on SGLT2’s having off target benefits.
I was just having a conversation with Opus about it.
I took it for a few days a few months ago, but then stopped. I just restarted 5 days ago after getting an rx for 20mg pills.
Opus wanted me to start at 10mg because I don’t have high bp. I asked him what benefits I could expect at 10mg vs 20mg and he said:
What you’d hope 10mg buys you long-term:
Blunt angiotensin II — less of the signal that drives vessel stiffening and injury
Cardiorenal protection — easier load on heart and kidneys over time
Kidney/protein protection — less albumin leak, slower kidney aging
Arterial stiffness — softer, more elastic vessels
Matches your ACE D/D — you make more angiotensin II than average, so blocking it fits your genetics
Same benefits at 10mg vs 20mg — just potentially weaker at 10mg, since these are dose-graded. You trade some effect for less BP drop.
Two you keep fully at 10mg (not dose-dependent):
24-hour coverage — the long half-life holds
Brain penetration — property of the drug, not the dose
PS, apparently there is no PPAR-y benefit we can expect to have at low doses. “He” seems to feel it would even very ify at 40mg. (I, of course, have no idea!).
A $399 Smart Ring Aims to Replace the 150-Year-Old Blood Pressure Cuff
A three-year-old startup says it has produced a smart ring that can track blood pressure as accurately as a traditional arm cuff and that — eventually — it could be able to make medical diagnoses. If the company, called Vital Signals, can successfully deliver on the promise, it would represent a significant breakthrough in consumer wearables.
The $399 Signal Ring is unique in that it doesn’t require a traditional blood pressure cuff for users to get started or periodically calibrate the data. And, unlike wearables from certain high-profile companies such as Apple Inc., it provides not just blood pressure trends, but actual readings.
Hilo.com now selling the Hilo Core continuous wear, band and BP cuff in the United States. $238.98 — Cuff and band $$89.99 + $149.99 for 1 year subscription.
“Next-generation blood pressure monitoring. The only clinically certified cuffless and continuous solution. Designed to support meaningful reductions in blood.”
I have a Katalyst that I sometimes bring when traveling
It seems to work.
But be aware to not overdo it, it there are potential risks of rhabdomyolysis (often shortened to “rhabdo”). When overworked muscle fibers break down and release their contents (particularly a protein called myoglobin) into the bloodstream, which can overwhelm and damage the kidneys in severe cases.
